D
Diagenode
Biotech & Life Sciences · Seraing, Belgium · Founded 2003
Epigenomics tools and diagnostics powering advanced disease insights MoreLess
Diagenode, now operating as Hologic Diagenode, is a Belgian life sciences company specializing in epigenomics profiling services, molecular diagnostics and sample preparation tools for next‑generation sequencing, proteomics and epigenetics research. Founded in 2003 in Liège/Seraing, it has built a comprehensive portfolio of instruments such as the Bioruptor sonicators, high‑quality reagent kits and extensively validated antibodies that standardize critical workflows including chromatin shearing, ChIP‑seq, ATAC‑seq and DNA methylation assays. These products are used globally by academic laboratories, biotechs, pharmaceutical companies and clinical research organizations to explore gene regulation and uncover novel biomarkers. Beyond tools, Diagenode offers full‑stack epigenomics and RNA‑seq services, covering experimental design, wet‑lab execution and advanced bioinformatics analysis. Its service offering spans chromatin immunoprecipitation sequencing (ChIP‑seq), ATAC‑seq, whole‑genome and reduced representation bisulfite sequencing (WGBS, RRBS), and a range of RNA‑sequencing approaches, including small RNA and CATS‑based low‑input workflows. This integrated model enables customers to outsource complex projects such as genome‑wide mapping of histone marks, methylation profiling and transcriptome characterization, accelerating discovery while ensuring data quality and reproducibility. In parallel, Diagenode has built a CE‑marked molecular diagnostics menu of more than 30 real‑time PCR assays targeting infectious agents involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis, among others. These assays, combined with the company’s epigenetics expertise, position it at the interface of research and clinical application, supporting both fundamental science and translational diagnostics development. Hologic’s 2021 acquisition of Diagenode, valuing the company at approximately $159 million on annual revenues above $30 million, reflects the strategic importance of its technologies and European footprint in the broader molecular diagnostics market. Keywords: Diagenode; Hologic Diagenode; epigenetics; epigenomics; DNA methylation; ChIP‑seq; ATAC‑seq; RNA‑seq; small RNA sequencing; next‑generation sequencing; molecular diagnostics; PCR assays; infectious disease diagnostics; life science tools; laboratory instruments; sample preparation; bioinformatics services; biomarker discovery; Belgium; Liège.
Company overview
Diagenode company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2003
- Headquarters
- Seraing, Belgium
- Employees
- 123
- Open positions
- 2
- Dealroom signal
- 66.6
- Investment activity
- 1 companies · latest Aug 2018
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Diagenode funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2021 | $159M | $159M | Hologic | ↗ |
| GRANT✓Other financing | Jan 2018 | $913K | — | Undisclosed | — |
| GRANT✓Other financing | Oct 2016 | $539K | — | Undisclosed | — |
| EARLY VC✓Equity / VC | Jun 2016 | $8.3M | $33M | Epimede · Wallonie Entreprendre · Capricorn Partners | ↗ |
| GRANT✓Other financing | Jan 2016 | $187K | — | Undisclosed | — |
| GRANT✓Other financing | Nov 2013 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $15M | 0% | $1.7M | 11.6% |
| 2025 | $15M | 0% | $1.7M | 11.6% |
| 2024 | $15M | 0% | $1.7M | 11.6% |
| 2023 | $15M | -59.1% | ||
| 2022 | $36M | — | ||
| 2021 | — | — | ||
| 2020 | — | — |
Growth signals
Diagenode website traffic
Latest recorded traffic for Diagenode is 17K monthly website visits, down 10.5% over the last three months. Diagenode's team declined 10.2% over the past year.
Hiring
Open positions at Diagenode
Current openings linked to this company in Dealroom.
Comparisons
Diagenode compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Diagenode investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Diagenode's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on Diagenode's cap table
Sourced from Dealroom's funding and investor records.





Global footprint
Where Diagenode has talent and traffic
team presence
In the news
Latest news about Diagenode
Recent press, funding announcements, and product moves mentioning Diagenode — open to read from the original sources.
Market sentiment
What the market is saying about Diagenode
An AI-synthesized read of the highest-engagement posts about Diagenode on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Diagenode’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








